Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switching to Stribild in Virologically Suppressed HIV-1 Patients
NCT01495702Phase 3Completed
- Sponsor
- Gilead Sciences
- Start
- Dec 2011
- Primary completion
- Nov 2013
- Modality
- Small Molecules
- Countries
- 12
01
Overview
A Phase 3 trial of emtricitabine + elvitegravir + cobicistat + tenofovir disoproxil in human immunodeficiency virus type 1 infection (HIV-1), sponsored by Gilead Sciences. Started Dec 2011; status: completed.
02
Drugs
emtricitabine + elvitegravir + cobicistat + tenofovir disoproxil
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT01495702.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01495702.